ClinicalTrials.gov
ClinicalTrials.gov Menu

Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease (STERMEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00912886
Recruitment Status : Completed
First Posted : June 3, 2009
Last Update Posted : April 11, 2013
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

June 2, 2009
June 3, 2009
April 11, 2013
September 2009
September 2011   (Final data collection date for primary outcome measure)
Plasma concentrations of PREGS determined by GC-MS [ Time Frame: At the day of diagnostic blood collection ]
Same as current
Complete list of historical versions of study NCT00912886 on ClinicalTrials.gov Archive Site
  • Memory scores of the RL-RI test according to the GROBER and BUSCKE test [ Time Frame: At the day of blood collection ]
  • Plasma concentrations of PREGS metabolites [ Time Frame: At the day of blood collection ]
Same as current
Not Provided
Not Provided
 
Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease
Neuroactive Steroids and Cognition in Humans: Pregnenolone Sulfate an Early Marker of the Memory Loss Associated With Alzheimer's Disease
The steroid pregnenolone sulfate (PREGS) may be one of the factors responsible for the memory decline related to normal aging or associated with Alzheimer's disease (AD). The purpose of this study is to determine whether plasma levels of PREGS are decreased patients with at mild to moderate AD compared with AD-free control subjects matched for gender and age and to see whether they are inversely correlated with the severity of memory deficits in AD patients. The hypothesis is that blood levels of PREGS are decreased with advanced age and with the stage of AD that would be positively correlated with memory deficits. Therefore PREGS could be considered as an early marker of the memory deficits in AD.

PREGS is a derivative of pregnenolone which the obligatory precursor of all steroid hormones originating from the gonads and adrenal glands. In rodents, PREGS has been demonstrated to improve memory performance in various behavioural tests. In humans, PREGS is one the most abundant circulating steroids. There are some indications about its decrease in blood during aging, and in brain samples from aged patients with AD, low concentrations of PREGS have been correlated with high levels of beta-amyloid peptide and phosphorylated tau protein. To date, a precise and rigorous evaluation of PREGS blood concentrations during aging is lacking and the relationship between these concentrations and the memory loss associated with AD has not been established.

Primary objective To show that plasma concentrations of PREGS are decreased in AD patients (" case ") compared to free-AD subjects (" controls "), matched for gender and age.

Secondary objectives

  • To show that plasma concentrations of PREGS are inversely correlated with the severity of memory deficits in AD patients.
  • To show that plasma concentrations of PREGS are correlated with the memory scores in the controls.
  • To show that plasma concentrations of PREGS decrease in the controls.
  • To search for a relationship between some of PREGS metabolites and age or the severity of memory deficits.

This is a case-control study that will comprise 200 subjects aged over 70 years, including 100 outpatients with mild to moderate AD and 100 AD-free volunteer controls matched on age and gender. These two groups will be stratified into age-sub-groups [70-74] [75-79] [80-84] [85-89] > 90 years and will include 10 men and 10 women per sub-group.

AD patients and controls will be enrolled and evaluated in the geriatric centres of 5 hospitals namely BICETRE, BROCA, PAUL BROUSSE, PITIE-SALPETRIERE and ROTHSCHILD. They will all be submitted to a clinical examination, biological analyses, cognitive tests and a brain magnetic resonance imaging scan. Blood will be collected from all subjects for steroid analysis by gas chromatography-mass spectrometry, a sensitive and accurate methodology that allows simultaneous quantification of several steroids in the same individual sample. PREGS and some of its metabolites will be identified and quantified at the "Institute medical of heath" (INSERM U788).

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Plasma and serum from AD patients and from Controls
Non-Probability Sample
  • AD Patients will be recruited among the new patients from the consultations of the geriatric centres involved in the study
  • Controls will be recruited from the consultations, associations of aged persons or among the relatives of the patient
Alzheimer Disease
Not Provided
  • 1: Case
    Patients with early and moderate AD
  • 2: Controls
    AD free volunteer-controls matched for gender and age
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
90
200
September 2011
September 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects aged over 70 years who have signed informed consent for participation to the study and are affiliated to a social security regimen.
  • For patients: subjects with probable AD according to the DSM-IV criteria and the NINCDS/ADRDA criteria and with mild to moderate probable AD: MMSE score> 15.
  • For Controls: subjects without cognitive deficits on neuropsychological tests: scores of MMSE > 26 and of the 5 Word test equal to 10/10 and of the Clock Drawing test equal to 7/7.

Exclusion Criteria:

  • Guardianship
  • History of cerebrovascular disease, Parkinson's disease, other known dementia, epilepsy
  • Major depression
  • Serious sensory disorders; deficits in language & comprehension
  • Serious heart or hepatic insufficiencies, renal or respiratory failures
  • Unstable diabetes or endocrine disorders, thyroid dysfunction, cancer, inflammatory syndrome, malnutrition
  • Cognitive training during the 6 previous months
  • Medications: steroids (HRT, androgens, corticoids), anti-depressants, cholinesterase inhibitors, thyroid hormones, synthetic anti-thyroids
  • Contraindications for MRI: metallic implants & claustrophobia
Sexes Eligible for Study: All
70 Years and older   (Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00912886
P071237
No
Not Provided
Not Provided
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Not Provided
Principal Investigator: Sebastien Weill-Engerer, MD Assistance Publique - Hôpitaux de Paris Hôpital Rothschild
Study Director: Yvette Akwa, PhD INSERM U788
Assistance Publique - Hôpitaux de Paris
April 2013